• Procyrion

  Participated · Series D · Jul 2019

  Procyrion is a Houston, TX-based medical device company developing the Aortix percutaneous mechanical circulatory support (pMCS) device, a catheter-deployed pump that harnesses fluid entrainment to move blood. Led by CEO Eric S. Fain, the company targets treatment options for patients with cardiac and renal impairment, including acute decompensated heart failure and cardiorenal syndrome. Aortix is limited by Federal law to investigational use only and is not approved for sale in any geography. The company plans to use the new financing to support the ongoing DRAIN-HF pivotal IDE trial evaluating Aortix in ADHF patients who remain congested despite standard medical therapy. Additional proceeds will fund internal programs to improve product manufacturability and to prepare for commercialization. Procyrion is developing Aortix, a catheter-deployed, intra-aortic percutaneous blood pump designed to reduce cardiac afterload while increasing renal blood flow for cardiorenal syndrome patients. The device is placed in the descending thoracic aorta and uses fluid entrainment to increase aortic velocity and flow without a valve. Procyrion plans to use the new funding to complete a pilot study and to support activities required for an FDA IDE submission for a pivotal trial. The company is clinical-stage and its Aortix device is not approved for use or sale. Procyrion is Houston-based and conceived at the Texas Heart Institute and Fannin Innovation Studio. To date the company has raised more than $59 million in funding. Procyrion is developing Aortix, described as the first catheter-deployed, intra-aortic pump designed for ambulatory use to unload the heart and improve renal perfusion. The device is thinner than a pencil and intended to be placed in a simple cath-lab procedure to help patients too sick for medication alone but not candidates for transplant or LVAD. Procyrion plans to advance Aortix into pilot trials in Acutely Decompensated Heart Failure patients and to further enhance the system's features and performance. The company is clinical-stage and Aortix is not approved for use or sale. Benjamin Hertzog, Ph.D., is named as Procyrion’s chief executive officer in the announcement. The device concept is credited to cardiologist Dr. Reynolds M. Delgado, III. Procyrion is described in the article as a Houston heart-failure biotech. The coverage notes the company has raised $10 million. The article does not provide details on Procyrion’s specific product(s) or pipeline. It does not disclose operating metrics such as revenue or user counts. The article also does not specify the investors or the instrument(s) used in the raise. No information on use of proceeds, prior financings, or founding year is provided in the article.

• Fe3 Medical

  Participated · Series B · Aug 2016

  Fe3 Medical is developing a transdermal patch that delivers iron across the skin to treat patients with iron-deficiency anemia. The patch is intended as an alternative to oral iron for nearly half of patients who cannot tolerate gastrointestinal side effects such as constipation, diarrhea, nausea and bloating. Led by CEO Mark Sieczkarek, the company relocated from InCube’s Silicon Valley lab to InCube’s San Antonio, TX facility. Fe3 is working on product development, clinical trials and regulatory submissions aimed at obtaining CE Mark and FDA approval for the patch. The company’s Series B has been extended, bringing additional capital to support those development and regulatory efforts. Fe3 Medical has developed a novel transdermal patch that delivers iron across the skin for patients with iron‑deficiency anemia. The patch offers an alternative to oral iron for nearly half of patients who cannot tolerate gastrointestinal side effects such as constipation, diarrhea, nausea and bloating. Fe3 is a spin‑out of InCube Labs, a multi‑disciplinary life‑sciences R&D lab with operations in San Jose and San Antonio. The company plans to use the funds to support clinical trials and the regulatory submissions required to obtain CE Mark and FDA approval for the transdermal patch. Fe3 is led by CEO Mark Sieczkarek and President Phil Morgan.

• Ensysce Biosciences

  Led · Equity · Jun 2012

  Ensysce Biosciences is developing chemically engineered drug platforms—TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance)—to reduce abuse and oral overdose risk for opioid therapies. Its lead candidate, PF614-MPAR, combines the PF614 opioid prodrug (activated by trypsin in the small intestine) with an MPAR mechanism intended to limit opioid release when excessive pills are ingested. PF614-MPAR has received Breakthrough Therapy designation from the FDA following initial clinical data from the PF614-101 study. Ensysce is initially developing PF614-MPAR for patients with severe pain and believes its approach could create a new class of opioids that maintain therapeutic exposure during prescribed use while restricting excess exposure during misuse. The company is exploring additional applications of its platforms for amphetamines and methadone. PF614-MPAR remains investigational and has not been approved by the FDA; additional studies are required to establish safety and effectiveness.

• Bi02 Medical

  Participated · Series B · Mar 2012

  Bio2 Medical is a Golden, CO-based developer of a catheter to protect critically ill patients from acute pulmonary embolism (PE). The company introduced the Angel® Catheter, an IVC filter that received FDA clearance for a prophylactic use indication. It recently closed a $3M second tranche of venture debt financing provided by Oxford Finance. The company intends to use the funds to further execute its U.S. commercialization plan for the Angel® Catheter, including hiring a sales team, building inventory and executing market development initiatives. Led by Chairman and Chief Executive Officer Christopher E. Banas, Bio2 Medical has to date raised $43.1M of institutional funding. BiO2 Medical develops the Angel® Catheter, a mechanical pulmonary embolism protection device with a prophylactic indication whose clinical trials were successfully completed. The catheter is designed as a femoral approach central venous catheter (CVC) that enables bedside venous access without the need for fluoroscopy and provides immediate pulmonary embolism protection through a permanently attached, 100% retrievable inferior vena cava (IVC) filter. The company is led by Chairman and CEO Christopher E. Banas. BiO2 intends to use new financing to support its US product launch, expand its US and OUS sales force, fund incremental R&D projects, and develop general infrastructure. The company is based in San Antonio, Texas and Golden, Colorado. Current operating metrics such as revenue or user numbers were not disclosed in the article. BiO2 Medical develops the Angel Catheter, an implantable device intended to prevent pulmonary embolisms in hospitalized patients at high risk, particularly those with severe head and spinal injuries for whom anticoagulants can be dangerous. The device is indicated for up to 30 days of use and holds a CE mark for sale in Europe; it remains investigational in the U.S. and is not FDA‑cleared. The company is conducting a 150‑patient, multicenter trial to evaluate the device’s efficacy. A regulatory filing shows BiO2 has raised $4 million so far as part of a $10 million round. The filing indicates the $4 million was provided by a single investor and does not specify the instrument type. BiO2 has raised more than $35 million since its founding in 2006 and is based in Texas. BiO2 Medical is a San Antonio, Texas–based medical device manufacturer developing the Angel™ Catheter, a combined central venous catheter and inferior vena cava (IVC) filter. The Angel Catheter is intended to protect critically ill patients from potentially fatal pulmonary embolism (PE). The company intends to use new funding to commercialize the Angel Catheter. BiO2 has R&D and manufacturing operations in Golden, Colorado. It is led by Chairman and CEO Christopher E. Banas and Chief Medical Officer Dr. Luis F. Angel. The company raised $12M in a Series C round to support these commercialization efforts. BiO2 Medical is a San Antonio, Texas–based medical device manufacturer developing the Angel™ Catheter, a combined central venous catheter and inferior vena cava (IVC) filter intended to protect critically ill patients from potentially fatal pulmonary embolism (PE). The company is led by Chairman and CEO Christopher E. Banas and Chief Medical Officer Dr. Luis F. Angel. BiO2 has corporate offices and R&D and manufacturing operations in Golden, Colorado. The Angel Catheter is positioned as a dual-function device combining central venous access with IVC filtration. The recent financing has supported completion of Design Verification Testing in support of a CE Mark submission, initiation of a first-in-human clinical study in Medellin, Colombia, and a Pre-IDE meeting with the FDA. Financially, BiO2 completed a $13.7M Series B round which included conversion of a $1.0M State of Texas Emerging Technology Fund award.

• Ortho Kinematics

  Participated · Equity · Nov 2009

  Ortho Kinematics is a privately held diagnostic technology company focused on spine imaging informatics and committed to the idea that spine motion matters. Its flagship product is the VMA (Vertebral Motion Analysis) for the radiographic assessment of spinal instability and alignment; the company developed the VMA-Align module to assess sagittal alignment. The VMA technology had a commercial launch in 2015 and VMA-Align was developed in 2016. Ortho Kinematics recently closed an $18.6 million Series D equity financing to support continued commercialization and further development of the technology. The company is ramping a broader commercial launch and will expand sales, marketing, manufacturing, and R&D activities to meet demand. Leadership and industry commentators emphasized the need for improved functional spine diagnostics and suggested patients will benefit from wider commercialization. Ortho Kinematics is a privately held diagnostic technology company focused on spine imaging informatics and the biomechanical assessment of spinal motion. Its flagship product, the VMA (Vertebral Motion Analysis), provides radiographic assessment of spinal motion and instability. OKI has commercially tested the VMA on over 4,000 patients, demonstrating clinical traction. The company plans to expand U.S. and OUS commercialization of the VMA and to launch several new product features. To support commercialization and reimbursement efforts it appointed Margie Hans as Director of Reimbursement and Health Policy. Ortho Kinematics is located in Austin, Texas and is using new financing to strengthen its cash position. Ortho Kinematics develops the VMA (Vertebral Motion Analysis), a radiographic motion-analysis product for assessing spinal motion and instability. The company is a privately held diagnostic technology firm focused on spine imaging informatics and works with clinicians, researchers, and developers. OKI secured FDA clearance for the VMA and completed a limited-scale commercial launch. It is currently ramping up efforts for a full-scale commercial launch within the U.S. and Europe. The company plans to expand sales and marketing and continue limited research and development to support adoption. Ortho Kinematics is located in Austin, Texas. Ortho Kinematics is a privately held diagnostic technology company focused on spine imaging informatics based in Austin, Texas. Its core product is the VMA (Vertebral Motion Analysis) platform, a proprietary technology that pairs with standard fluoroscopes to capture video x-ray images while patients perform flexion, extension, and lateral bending movements. Proprietary image recognition software tracks motion at each vertebral level to produce biomechanical data; the VMA has patented intellectual property and received U.S. FDA clearance earlier this year. OKI is in a limited scale beta launch with strategic partners. The company plans to use new funding to commercialize VMA and to complete and expand its enterprise platform to assess the cervical spine in addition to current lumbar assessments. Leadership states the goal is to advance diagnostic standards for spine motion assessments. Ortho Kinematics develops the KineGraph VMA™, a vertebral motion analyzer that uses standard fluoroscopy and proprietary image-recognition software to track intervertebral movement. The device captures video images of the spine while patients are guided through flexion, extension, and side‑bending to produce movement information at each vertebral level. The KineGraph VMA™ is an investigational device currently in clinical studies at seven sites across the United States and United Kingdom. The company plans to use the new funds to expand its ongoing clinical study, pursue regulatory clearance, and hire key sales personnel. Ortho Kinematics is led by founder and CEO Adam Deitz and is based in Austin, Texas. It closed $2M of new funding in the announced round.

No current team members are available.